US2024408096A1PendingUtilityA1
Dosing regimens for oral alk2 kinase inhibitors
Est. expiryDec 21, 2040(~14.4 yrs left)· nominal 20-yr term from priority
A61K 9/4825C07D 403/12C07D 491/048C07D 495/04A61K 31/53C07D 487/04A61K 31/519C07D 513/04C07D 471/04C07D 403/14A61K 9/0053A61P 19/04A61K 31/4725A61K 31/4709A61K 31/4164A61K 31/4178A61K 31/517A61P 35/00
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed are dosage forms of compounds and pharmaceutically acceptable salts thereof, which are inhibitors of ALK2 kinase, including mutant forms of ALK2. Also disclosed are methods of using the oral dosage forms in the treatment or prevention of a disease or condition whose treatment would benefit from ALK2 kinase inhibition (e.g., Fibrodysplasia Ossificans Progressiva and cancer).
Claims
exact text as granted — not AI-modified1 . An oral dosage form, comprising a compound selected from:
or a pharmaceutically acceptable salt or prodrug thereof; and
a pharmaceutically acceptable carrier.
2 . The oral dosage form of claim 1 , comprising about 10 mg to about 500 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
3 . The oral dosage form of claim 1 , comprising about 10 mg to about 250 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
4 . The oral dosage form of any one of claims 1-3 , wherein the oral dosage form is a capsule.
5 . The oral dosage form of claim 4 , wherein the capsule is a hard or soft gelatin capsule.
6 . A method of inhibiting ALK2 kinase, comprising orally administering to a subject in need thereof a therapeutically effective amount of a compound selected from:
or a pharmaceutically acceptable salt or prodrug thereof.
7 . The method of claim 6 , wherein the ALK2 kinase comprises a mutation.
8 . The method of claim 7 , wherein the mutation is an activating mutation.
9 . The method of claim 8 , wherein the activating mutation is R206H.
10 . A method of treating fibrodysplasia ossificans progressiva, comprising orally administering to a subject in need thereof a therapeutically effective amount of a compound selected from:
or a pharmaceutically acceptable salt or prodrug thereof.
11 . A method of treating cancer, comprising orally administering to a subject in need thereof a therapeutically effective amount of a compound selected from:
or a pharmaceutically acceptable salt or prodrug thereof.
12 . The method of claim 11 , wherein the cancer is selected from tumors of the central nervous system, breast cancer, prostate cancer, skin cancer (including basal cell carcinoma cell carcinoma, squamous cell carcinoma and melanoma), cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, glioma, pancreatic cancer, stomach cancer, liver cancer, colon cancer, renal cancer, bladder cancer, oesophageal cancer, cancer of the larynx, cancer of the parotid, cancer of the biliary tract, rectal cancer, endometrial cancer, adenocarcinomas, small cell carcinomas, neuroblastomas, mesotheliomas, adrenocortical carcinomas, epithelial carcinomas, desmoid tumors, desmoplastic small round cell tumors, endocrine tumors, Ewing sarcoma family tumors, germ cell tumors, hepatoblastomas, hepatocellular carcinomas, non-rhabdomyosarcoma, soft tissue sarcomas, osteosarcomas, peripheral primitive neuroectodermal tumors, retinoblastomas, rhabdomyosarcomas, and Wilms tumors.
13 . The method of claim 11 , wherein the cancer is a glioma.
14 . The method of claim 13 , wherein the glioma is diffuse intrinsic pontine glioma.
15 . The method of claim 6 , wherein the therapeutically effective amount is about 10 to about 500 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
16 . The method of claim 6 , wherein the therapeutically effective amount is about 10 to about 250 mg of the compound or a pharmaceutically acceptable salt or prodrug thereof.
17 . The method of claim 6 , wherein the compound or a pharmaceutically acceptable salt or prodrug thereof is administered once daily.
18 . The method of claim 6 , wherein the length of administration is 1 day to 6 months.
19 . The method of claim 18 , wherein the length of administration is 7 days, 14 days, 21 days, or 28 days.
20 - 22 . (canceled)
23 . The method of claim 6 , wherein the compound or a pharmaceutically acceptable salt or prodrug thereof is administered as a single oral dosage form.
24 . The method of claim 6 , wherein the compound or a pharmaceutically acceptable salt or prodrug thereof is administered as a single hard or soft gelatin capsule.
25 . (canceled)Join the waitlist — get patent alerts
Track US2024408096A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.